Company Filing History:
Years Active: 2013-2025
Title: Masashi Toyofuku: Innovator in Pharmaceutical Patents
Introduction
Masashi Toyofuku is a prominent inventor based in Kanagawa, Japan, recognized for his substantial contributions to the field of pharmaceuticals. With an impressive portfolio of 20 patents, Toyofuku has focused on developing innovative compounds that aim to address various mental health and neurodegenerative disorders.
Latest Patents
Toyofuku’s recent inventions showcase his commitment to tackling complex medical challenges. His patent titled "Heterocyclic compound and use thereof" introduces a compound that exhibits AMPA receptor potentiating action. This compound holds promise as a therapeutic option for conditions such as depression, schizophrenia, Alzheimer’s disease, and attention deficit hyperactivity disorder (ADHD).
Another significant innovation is his "Cyclopropanamine compound and use thereof", which describes a compound that inhibits lysine-specific demethylase-1. This invention is positioned as a potential medicament for a range of disorders, including schizophrenia, various developmental disorders, neurodegenerative diseases, and epilepsy.
Career Highlights
Masashi Toyofuku is employed at Takeda Pharmaceutical Company Limited, a leading global biopharmaceutical company. His work in the pharmaceutical industry has not only contributed to advancing medical science but has also positioned him as a key figure in innovative drug development.
Collaborations
Throughout his career, Toyofuku has collaborated with notable colleagues such as Shinji Nakamura and Eiji Honda. These partnerships have helped foster creative and effective solutions to complex problems in drug development, further bolstering the potential impact of his patented inventions.
Conclusion
Masashi Toyofuku exemplifies the spirit of innovation within the pharmaceutical industry. With a dedicated focus on creating impactful therapeutic compounds, his patents represent significant advancements in the treatment of mental health and neurodegenerative diseases. His ongoing efforts at Takeda Pharmaceutical Company Limited continue to pave the way for future breakthroughs in health care.